How much funding has Egle Therapeutics raised?

Egle Therapeutics has raised $52.4M in total funding, most recently a Series A round.

Who are Egle Therapeutics's investors?

Egle Therapeutics's investors include EQT AB.

When was Egle Therapeutics founded?

Egle Therapeutics was founded in 2020.

Where is Egle Therapeutics headquartered?

Egle Therapeutics is headquartered in Suresnes, France.

What industry is Egle Therapeutics in?

Egle Therapeutics operates in Biotech, Pharmaceuticals.

Egle Therapeutics

We modulate regulatory T cells to rebalance immunity

Suresnes, France · Founded 2020 · $52.4M raised

Biotech

Pharmaceuticals

Headquarters: Suresnes
Founded: 2020
Website: egle-tx.com

Total Funding: $52.4M
Last Round: $52.4M Series AOct 2021
Rounds: 1

About

Founded in 2020 as a spin-off from Institut Curie in Paris, Egle Therapeutics is a clinical-stage biotech company developing precision immunotherapies that modulate regulatory T cells (Tregs) to rebalance immunity in cancer and autoimmune diseases. Its lead oncology program EGL-001 (an antagonist IL-2 mutein fused to a CTLA-4 antibody) is in Phase I trials, while EGL-003 for autoimmune disease entered Phase I in 2025.

Summary

Egle Therapeutics is a Biotech company based in Suresnes, France, founded in 2020. It has raised $52.4M in total across 1 round, most recently a $52.4M Series A round in Oct 2021. Investors include EQT AB.